

EDEN BIOSCIENCE CORP
Form 8-K
July 26, 2005

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: July 26, 2005
(Date of earliest event reported)

Eden Bioscience Corporation
(Exact name of registrant as specified in its charter)
WA
(State or other jurisdiction
of incorporation) 0-31499
(Commission File Number) 91-1649604
(IRS Employer
Identification Number)
3830 Monte Villa Parkway, Suite 100
(Address of principal executive offices) 98021-7266
(Zip Code)
425-806-7300
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On July 26, 2005, Eden Bioscience Corporation issued a press release announcing the Company's financial results for the second quarter ended June 30, 2005. The press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

The information in this current report, including but not limited to Exhibit 99.1, is being furnished and shall not be deemed "filed" for purpose of Section 18 of the Securities and Exchange Act of 1934, or otherwise subject to the liabilities of that Section. The information in this current report, including but not limited to Exhibit 99.1, shall not be incorporated into any registration statement or other document filed pursuant to the Securities Act of 1934, except as shall be expressly set forth by specific reference in such filings.

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:

None

(b) Pro forma financial information:

None

(c) Exhibits

99.1 Press Release of Eden Bioscience Corporation dated July 26, 2005

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 26, 2005

EDEN BIOSCIENCE CORPORATION

By: /s/ Bradley S. Powell

Bradley S. Powell

Chief Financial Officer

Exhibit Index **Exhibit No.** **Description** 99.1 Press Release of Eden Bioscience Corporation dated July 26, 2005